TD Cowen Maintains Buy on United Therapeutics, Raises Price Target to $400
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Joseph Thome has maintained a Buy rating on United Therapeutics and increased the price target from $350 to $400.
October 21, 2024 | 5:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen analyst Joseph Thome has reiterated a Buy rating for United Therapeutics and increased the price target from $350 to $400, indicating confidence in the company's future performance.
The increase in price target from $350 to $400 by TD Cowen suggests a positive outlook on United Therapeutics' future performance. This is likely to boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100